Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTH | P32929 | 3/20 | 0.53 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 13/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2236093 | 1.00 | CTH (0.53) | CTHFGF23NFE2L2ALDH1A1LMNA | |
| SCHEMBL20913089 | 1.00 | CTH (0.53) | CTHFGF23NFE2L2ALDH1A1LMNA | |
| SCHEMBL30139582 | 1.00 | CTH (0.53) | CTHFGF23NFE2L2ALDH1A1LMNA | |
| SCHEMBL18828103 | 0.80 | CTH (0.53) | CTHNFE2L2LMNARAB9ASMN1; SMN2 | |
| SCHEMBL22579089 | 0.80 | CTH (0.53) | CTHNFE2L2LMNARAB9ASMN1; SMN2 | |
| SCHEMBL20597363 | 0.78 | FGF23 (0.61) | CTHFGF23ALDH1A1LMNAUSP2 | |
| SCHEMBL29402625 | 0.78 | FGF23 (0.45) | CTHFGF23ALDH1A1LMNARAB9A | |
| SCHEMBL16712006 | 0.78 | FGF23 (0.45) | CTHFGF23ALDH1A1LMNARAB9A | |
| SCHEMBL28350245 | 0.77 | — | — | |
| SCHEMBL21645883 | 0.76 | CTH (0.54) | CTHFGF23ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697769-B1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | CENTRE NAT RECH SCIENT (FR) | 2023-02-15 | — | — | EP | disclosed |
| US-11370772-B2 | 6-Substituted 3-Fluoro-2-Pyridinaldoxime, 3-Fluoro-2-pyridine hydroxamic acid, and 3-Fluoro-2-Pyridinamidoxime scaffolds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-06-28 | — | — | US | disclosed |
| US-11370772-B2 | 6-Substituted 3-Fluoro-2-Pyridinaldoxime, 3-Fluoro-2-pyridine hydroxamic acid, and 3-Fluoro-2-Pyridinamidoxime scaffolds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-06-28 | — | — | US | disclosed |
| EP-3697769-A1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | Centre National De La Recherche Scientifique (FR) | 2020-08-26 | — | — | EP | disclosed |
| US-20200255399-A1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | UNIVERSITÉ DE STRASBOURG (50%) (FR) | 2020-08-13 | — | — | US | disclosed |
| WO-2019076986-A1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-04-25 | — | — | WO | disclosed |
| EP-3473618-A1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-04-24 | — | — | EP | disclosed |
| EP-3271350-A1 | SUBSTITUTED PYRIMIDINYLOXY PYRIDINE DERIVATIVES AS HERBICIDES | E. I. du Pont de Nemours and Company (US) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016149315-A1 | SUBSTITUTED PYRIMIDINYLOXY PYRIDINE DERIVATIVES AS HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2016-09-22 | — | — | WO | disclosed |
| CN-102395583-B | Isoxazole derivatives | HOFFMANN LA ROCHE | 2015-04-01 | — | — | CN | disclosed |
| EP-2533642-A1 | BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | Vanderbilt University (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011100614-A1 | BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| EP-1877399-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114706-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| US-7037921-B2 | Useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by multidrug resistance protein MRP1 | ELI LILLY AND COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1392702-B1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040097507-A1 | Compounds and methods for inhibiting mrp1 | BONJOUKLIAN ROSANNE (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1392702-A1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002081482-A1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097507-A1 | Compounds and methods for inhibiting mrp1 | ABCC1, ABCB1, ABCB11 | CTH 2237/4885FGF23 4540/4885NFE2L2 967/4885 |
| US-20200255399-A1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | PNPO, ACHE, PSEN2 | CTH 1040/4885FGF23 1239/4885NFE2L2 901/4885 |
| US-11370772-B2 | 6-Substituted 3-Fluoro-2-Pyridinaldoxime, 3-Fluoro-2-pyridine hydroxamic acid, and 3-Fluoro-2-Pyridinamidoxime scaffolds | PNPO, ACHE, PSEN2 | CTH 1040/4885FGF23 1239/4885NFE2L2 901/4885 |
| US-20080188478-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | CTH 1563/4885FGF23 2246/4885NFE2L2 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.